Richard T Hoppe

List of Publications by Year
in descending order

121	10,706	94269 37	30848 102
papers	citations	h-index	g-index

123	123	123	10194
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood, 2022, 140, 419-437.	0.6	58
2	The Stanford Volumetric Modulated Arc Therapy Total Body Irradiation Technique. Practical Radiation Oncology, 2022, 12, 245-258.	1.1	13
3	Volumetric modulated arc therapy total body irradiation in pediatric and adolescent/young adult patients undergoing stem cell transplantation: Early outcomes and toxicities. Pediatric Blood and Cancer, 2022, 69, e29689.	0.8	6
4	Low-dose total skin electron beam therapy for refractory cutaneous CD30 positive lymphoproliferative disorders. Journal of Dermatological Treatment, 2021, 32, 101-103.	1.1	1
5	A Preliminary Report of Gonadal-Sparing TBI Using a VMAT Technique. Practical Radiation Oncology, 2021, 11, e134-e138.	1.1	9
6	Stage Iâ€“II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy. Leukemia and Lymphoma, 2021, 62, 1840-1849.	0.6	1
7	Radiation Therapy for Primary Cutaneous Gamma Delta Lymphoma Prior to Stem Cell Transplantation. Cancer Investigation, 2021, , 1-11.	0.6	0
8	Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and SÃ©zary Syndrome. Advances in Radiation Oncology, 2021, 6, 100629.	0.6	12
9	Long-Term Outcomes of Patients With Early Stage Nonbulky Hodgkin Lymphoma Treated With Combined Modality Therapy in the Stanford V Trials (the G4 and G5 Studies). International Journal of Radiation Oncology Biology Physics, 2021, 110, 444-451.	0.4	3
10	Technical report: 3D-printed patient-specific scalp shield for hair preservation in total skin electron beam therapy. Technical Innovations and Patient Support in Radiation Oncology, 2021, 18, 12-15.	0.6	3
11	Use of cardiac radiation therapy as bridging therapy to CARâ€T for relapsed pediatric Bâ€cell acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2021, 68, e28870.	0.8	8
12	Therapeutic and Immunologic Responses Elicited By in Situ Vaccination with CpG, Ibrutinib, and Low-Dose Radiation. Blood, 2021, 138, 3539-3539.	0.6	0
13	In Situ Vaccination Induces Changes in Follicular Lymphoma Tumor Cells That Correlate with Abscopal Clinical Regressions. Blood, 2021, 138, 2407-2407.	0.6	0
14	The Meaningless Meaning of Mean Heart Dose in Mediastinal Lymphoma in the Modern Radiation Therapy Era. Practical Radiation Oncology, 2020, 10, e147-e154.	1.1	51
15	Keep the Dose Low. Keep the Fields Tight. International Journal of Radiation Oncology Biology Physics, 2020, 106, 15.	0.4	0
16	Eli J. Glatstein: A Steward Extraordinaire of Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2020, 107, 1-5.	0.4	2
17	Hodgkin lymphoma. Nature Reviews Disease Primers, 2020, 6, 61.	18.1	103
18	Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Institution Study. JCO Oncology Practice, 2020, 16, e902-e911.	1.4	1

#	Article	IF	Citations
19	Long-term outcomes of patients with unfavorable stage Iâ€“II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation. Leukemia and Lymphoma, 2020, 61, 2428-2434.	0.6	3
20	Long-Term Outcomes in 10-Year Survivors of Early-Stage Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 107, 522-529.	0.4	2
21	Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood, 2020, 135, 2365-2374.	0.6	30
22	Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal. Science Translational Medicine, 2020, 12, .	5.8	47
23	Tomayto, tomahto: prescription dose and mean heart dose in evaluating the cardiac impact of involved-field radiation therapy for Hodgkin lymphoma survivors. Acta OncolÃ³gica, 2019, 58, 1783-1785.	0.8	2
24	Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin. Journal of the American Academy of Dermatology, 2019, 81, 970-976.	0.6	14
25	20 Gy Versus 30 Gy: Will it Make a Difference?. International Journal of Radiation Oncology Biology Physics, 2019, 105, 102-103.	0.4	0
26	Volumetric Modulated Arc Therapy and 3-Dimensional Printed Bolus in the Treatment of Refractory Primary Cutaneous Gamma Delta Lymphoma of the Bilateral Legs. Practical Radiation Oncology, 2019, 9, 220-225.	1.1	4
27	Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood, 2019, 133, 237-245.	0.6	85
28	A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma. Blood, 2019, 134, 2834-2834.	0.6	1
29	The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1100-1118.	0.4	46
30	Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy. Radiotherapy and Oncology, 2018, 129, 507-512.	0.3	1
31	In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. Cancer Discovery, 2018, 8, 1258-1269.	7.7	136
32	Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort. Blood, 2018, 132, 4638-4638.	0.6	0
33	No Utility of Routine Laboratory Testing during Surveillance in Detecting Relapse in Patients with Classic Hodgkin Lymphoma in First Remission. Blood, 2018, 132, 615-615.	0.6	0
34	Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee. International Journal of Radiation Oncology Biology Physics, 2017, 99, 825-842.	0.4	66
35	Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: A subset with possible durable remission without transplantation. JAAD Case Reports, 2017, 3, 310-315.	0.4	14
36	Post-treatment surveillance imaging in lymphoma. Seminars in Oncology, 2017, 44, 310-322.	0.8	4

#	Article	IF	Citations
37	Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern Era. Journal of Clinical Oncology, 2016, 34, 1443-1447.	0.8	31
38	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Journal of Clinical Oncology, 2016, 34, 2690-2697.	0.8	634
39	How I treat mycosis fungoides and SÃ©zary syndrome. Blood, 2016, 127, 3142-3153.	0.6	138
40	Classical Hodgkin Lymphoma with Reduced Î²2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunology Research, 2016, 4, 910-916.	1.6	146
41	2 Gyâ€‰Ã—â€‰2 for palliative treatment of mantle cell lymphoma. Leukemia and Lymphoma, 2016, 57, 2219-2221.	0.6	4
42	Partial orbit irradiation achieves excellent outcomes for primary orbital lymphoma. Practical Radiation Oncology, 2016, 6, 255-261.	1.1	11
43	A single-institution retrospective analysis of outcomes for stage Iâ€“II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Leukemia and Lymphoma, 2016, 57, 604-608.	0.6	12
44	A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT). Blood, 2016, 128, 4165-4165.	0.6	5
45	Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials. Journal of the American Academy of Dermatology, 2015, 72, 286-292.	0.6	156
46	Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era. International Journal of Radiation Oncology Biology Physics, 2015, 92, 99-106.	0.4	13
47	Modern Radiation Therapy for Primary Cutaneous Lymphomas: Field and Dose Guidelines From theÂInternational Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 92, 32-39.	0.4	150
48	Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 92, 11-31.	0.4	303
49	Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era. International Journal of Radiation Oncology Biology Physics, 2015, 92, 67-75.	0.4	9
50	The Paris Conference â€œLa RadiothÃ©rapie de la Maladie de Hodgkinâ€: A First Step in the Cure ofÂHodgkin Disease. International Journal of Radiation Oncology Biology Physics, 2015, 92, 3-4.	0.4	1
51	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Blood, 2015, 126, 176-176.	0.6	4
52	Comment on: â€œClinical Features, Management, and Prognosis of an International Series of 161 Patients With Limitedâ€Stage Diffuse Large Bâ€Cell Lymphoma of the Bone (the IELSGâ€14 Study)â€. Oncologist, 2014, 19, 1289-1289.	1.9	1
53	Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG). International Journal of Radiation Oncology Biology Physics, 2014, 89, 854-862.	0.4	479
54	Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and SÃ©zary Syndrome (SS). Blood, 2014, 124, 2544-2544.	0.6	15

#	Article	IF	Citations
55	Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma. Blood, 2014, 124, 3092-3092.	0.6	13
56	Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides or Sezary Syndrome: Final Results Show Significant Clinical Activity and Suggest Correlation with CD30 Expression. Blood, 2014, 124, 804-804.	0.6	3
57	Value of surveillance studies for patients (pts) with stage I-II diffuse large B-cell lymphoma (DLBCL) in the rituximab (R) era.. Journal of Clinical Oncology, 2014, 32, 8544-8544.	0.8	0
58	Poster - Thur Eve - 38: Feasibility of a Table-Top Total Body Irradiation Technique using Robotic Couch Motion. Medical Physics, 2014, 41, 15-15.	1.6	0
59	Use of High-Throughput Sequencing (HTS) of TCRÃŸ to Determine the Kinetics of Graft-Versus-Lymphoma (GVL) Effect and T-Cell Repertoire Profiles after Allogeneic Transplant. Blood, 2014, 124, 2473-2473.	0.6	0
60	A Cutaneous Lymphoma International Consortium â€˜CLICâ€™ study of Prognostic Parameters in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Progress Towards Establishing a Prognostic Index to Augment Clinical Staging. Blood, 2014, 124, 1621-1621.	0.6	2
61	Evolution of the techniques of radiation therapy in the management of lymphoma. International Journal of Clinical Oncology, 2013, 18, 359-363.	1.0	15
62	Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. Blood, 2013, 122, 4277-4277.	0.6	3
63	Either Combined-Modality Or Radiotherapy Alone Provide Favorable Outcome In Stage I-II Mantle Cell Lymphoma: A Report Of 82 Patients From The International Lymphoma Radiation Oncology Group (ILROG). Blood, 2013, 122, 4292-4292.	0.6	1
64	A Tribute to Malcolm A. Bagshawâ€”An Innovative Physician Who Soared to Success. International Journal of Radiation Oncology Biology Physics, 2012, 83, 6-7.	0.4	1
65	Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy. Hematology American Society of Hematology Education Program, 2012, 2012, 313-321.	0.9	2
66	Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression. Blood, 2012, 120, 797-797.	0.6	15
67	in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses. Blood, 2012, 120, 3703-3703.	0.6	0
68	Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years. Blood, 2012, 120, 4779-4779.	0.6	0
69	Radiotherapy Planning for the Lymphomas: Expanding Roles for Biologic Imaging. Frontiers of Radiation Therapy and Oncology, 2011, 43, 331-343.	1.4	2
70	Treatment strategies in limited stage follicular NHL. Best Practice and Research in Clinical Haematology, 2011, 24, 179-186.	0.7	6
71	Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. Blood, 2011, 118, 1603-1603.	0.6	3
72	Graft-Versus-Lymphoma Effect After Non-Myeloablative Allogeneic Transplant Induces Molecular Remission Assessed by High-Throughput Sequencing of T Cell Receptor in Patients with Advanced Stage Mycosis Fungoides and Sezary Syndrome. Blood, 2011, 118, 3114-3114.	0.6	0

#	Article	IF	Citations
73	Frontline Therapy of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Rituximab: The Stanford University Experience. Blood, 2011, 118, 2686-2686.	0.6	3
74	In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study. Journal of Clinical Oncology, 2010, 28, 4324-4332.	0.8	450
75	A Randomized Phase III Trial of ABVD Vs. Stanford V +/â˜ Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496). Blood, 2010, 116, 415-415.	0.6	18
76	Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496. Blood, 2010, 116, 416-416.	0.6	8
77	Outcome of Patients with Advanced Hodgkin Lymphoma Who Are Either Refractory to or Relapsed After Primary Therapy with the Stanford V Regimen. Blood, 2010, 116, 4828-4828.	0.6	0
78	Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin's Disease: Mature Results of the G4 Trial.. Blood, 2009, 114, 1670-1670.	0.6	6
79	Tolerance and Chimerism after Renal and Hematopoietic-Cell Transplantation. New England Journal of Medicine, 2008, 358, 362-368.	13.9	475
80	Chimerism and Tolerance after Combined Human Kidney and Hematopoietic Cell Transplantation Using Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte Globulin.. Blood, 2008, 112, 2174-2174.	0.6	1
81	Revised Response Criteria for Malignant Lymphoma. Journal of Clinical Oncology, 2007, 25, 579-586.	0.8	4,061
82	Hodgkin's Lymphoma: The Role of Radiation in the Modern Combined Strategies of Treatment. Hematology/Oncology Clinics of North America, 2007, 21, 915-927.	0.9	6
83	Survival in Follicular Lymphoma: The Stanford Experience, 1960â€“2003.. Blood, 2007, 110, 3428-3428.	0.6	7
84	Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma: Clinical and Molecular Characterization of a Subset with Worse Outcome.. Blood, 2007, 110, 3573-3573.	0.6	0
85	Hodgkin's disease limited to intrathoracic sites. Cancer, 2006, 52, 8-13.	2.0	46
86	Preliminary Report on a Phase I/II Study of Intratumoral Injection of PF-3512676 (CpG 7909), a TLR9 Agonist, Combined with Radiation in Recurrent Low-Grade Lymphomas.. Blood, 2006, 108, 2716-2716.	0.6	3
87	Protective Conditioning for Acute Graft-versus-Host Disease. New England Journal of Medicine, 2005, 353, 1321-1331.	13.9	319
88	Assessment of Favorable (F) Versus Unfavorable (U) Early Stage Hodgkinâ€™s Disease (HD); the Stanford V + Radiotherapy (RT) Experience.. Blood, 2005, 106, 1932-1932.	0.6	17
89	Efficacy and Late Effects of Stanford V Chemotherapy and Radiotherapy in Untreated Hodgkinâ€™s Disease: Mature Data in Early and Advanced Stage Patients.. Blood, 2004, 104, 308-308.	0.6	22
90	Marked Improvement in Staging Accuracy in Mycosis Fungoides/Seìzary Syndrome Using Integrated Positron Emission Tomography and Computed Tomography (PET/CT).. Blood, 2004, 104, 3127-3127.	0.6	0

#	Article	IF	Citations
91	Mycosis fungoides: radiation therapy. Dermatologic Therapy, 2003, 16, 347-354.	0.8	98
92	Hodgkin??s Disease. Cancer Journal (Sudbury, Mass), 2002, 8, 425-431.	1.0	2
93	Natural Killer/Natural Killer-Like T-Cell Lymphoma, CD56+, Presenting in the Skin: An Increasingly Recognized Entity With an Aggressive Course. Journal of Clinical Oncology, 2001, 19, 2179-2188.	0.8	153
94	Role of histology in providing prognostic information in mycosis fungoides. Journal of Cutaneous Pathology, 1998, 25, 311-315.	0.7	31
95	Comparison Between Conventional Salvage Therapy and High-Dose Therapy With Autografting for Recurrent or Refractory Hodgkin's Disease. Blood, 1997, 89, 814-822.	0.6	209
96	Treatment of early-stage gastric lymphoma. Journal of Surgical Oncology, 1994, 57, 78-86.	0.8	11
97	Mycosis fungoides skin lesions contain CD8+ tumor-infiltrating lymphocytes expressing an activated, MHC-restricted cytotoxic T-lymphocyte phenotype. Journal of Cutaneous Pathology, 1994, 21, 151-156.	0.7	54
98	EXPRESSION OF CLASS II MAJOR HISTOCOMPATIBILITY ANTIGENS BY KERATINOCYTES IN CUTANEOUS T CELL LYMPHOMA. International Journal of Dermatology, 1994, 33, 346-350.	0.5	7
99	Changes in marital and sexual functioning in long-term survivors and their spouses: Testicular cancer versus hodgkin's disease. Psycho-Oncology, 1992, 1, 89-103.	1.0	42
100	Metastatic Carcinoma in Lymph Nodes Simulating â€œSyncytial Variantâ€•of Nodular Sclerosing Hodgkin's Disease. American Journal of Clinical Pathology, 1991, 96, 589-593.	0.4	17
101	Prognostic factors for patients with diffuse large cell or immunoblastic non-Hodgkin's lymphomas: Experience of the non-Hodgkin's lymphoma pathologic classification project. Medical and Pediatric Oncology, 1990, 18, 89-96.	1.0	17
102	Radiation therapy in the management of bulky mediastinal Hodgkin's disease. Cancer, 1990, 66, 75-79.	2.0	15
103	Treatment of lupus nephritis with total lymphoid irradiation. observations during a 12â€“79-month followup. Arthritis and Rheumatism, 1988, 31, 850-858.	6.7	21
104	Sustained improvement of intractable rheumatoid arthritis after total lymphoid irradiation. Arthritis and Rheumatism, 1983, 26, 937-946.	6.7	64
105	Ointment-based mechlorethamine treatment for mycosis fungoides. Cancer, 1983, 52, 2214-2219.	2.0	49
106	Central nervous system involvement in non-Hodgkin's lymphoma: An analysis of 105 cases. Cancer, 1982, 49, 586-595.	2.0	330
107	Hodgkin's Disease: A clinicopathologic study of 659 cases. Cancer, 1982, 49, 1848-1858.	2.0	206
108	Morphologic types of diffuse large-cell lymphoma. Cancer, 1982, 50, 690-695.	2.0	60

#	Article	IF	Citations
109	Non-hodgkin's lymphoma presenting as thyroid enlargement. Cancer, 1981, 48, 2712-2716.	2.0	44
110	Cutaneous malignant lymphoma: A pathologic study of 50 cases with clinical analysis of 37. Cancer, 1981, 47, 300-310.	2.0	116
111	Lymph node biopsy in mycosis fungoides. Cancer, 1981, 47, 351-359.	2.0	76
112	Hodgkin's disease at autopsy: 1972â€“1977. Cancer, 1981, 47, 1852-1862.	2.0	61
113	Nodular lymphoma. Clinicopathologic correlations of parafollicular small lymphocytes and degree of nodularity. Cancer, 1980, 45, 2364-2367.	2.0	13
114	Prognostic factors in pathological stage IIIA Hodgkin's disease. Cancer, 1980, 46, 1240-1246.	2.0	117
115	Alternating chemotherapy and irradiation in the treatment of advanced Hodgkin's disease. Cancer, 1979, 43, 472-481.	2.0	55
116	Non-hodgkin's lymphoma.A study of the evolution of the disease based upon 92 autopsied cases. Cancer, 1979, 44, 529-542.	2.0	145
117	Arthritis in a patient with mycosis fungoides: complete remission after radiotherapy. Arthritis and Rheumatism, 1979, 22, 424-425.	6.7	19
118	Topical mechlorethamine therapy for mycosis fungoides. British Journal of Dermatology, 1977, 97, 547-550.	1.4	33
119	The long term effects of radiation on T and B lymphocytes in the peripheral blood after regional irradiation. Cancer, 1977, 40, 2071-2078.	2.0	71
120	The long term effects of radiation on T and B lymphocytes in the peripheral blood after regional irradiation. , 1977, 40, 2071.		1
121	Carcinoma of the nasopharynx.Eighteen years' experience with megavoltage radiation therapy. Cancer, 1976, 37, 2605-2612.	2.0	222